In a regulatory filing, Lucid Diagnostics (LUCD) disclosed that its director Dennis Matheis bought 350K shares of common stock as part of option exercise on May 20th in a total transaction size of $457.6K.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics files to sell 36.98M shares of common stock for holders
- Lucid Diagnostics Reports Increased Losses Amid Revenue Decline
- Anticipated Medicare Coverage and Strategic Positioning Drive Buy Rating for Lucid Diagnostics
- Lucid Diagnostics: Strong Cash Position and Growing EsoGuard Test Volumes Justify Buy Rating
- Lucid Diagnostics Reports Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue